Suppr超能文献

基于网络药理学分析银杏叶治疗阿尔茨海默病的潜力及机制

Analysis of the potential and mechanism of Ginkgo biloba in the treatment of Alzheimer's disease based on network pharmacology.

作者信息

Huang Xue-Yan, Li Ting-Ting, Zhou Lin, Liu Tao, Xiong Liu-Lin, Yu Chang-Yin

机构信息

Department of Neurology Affiliated Hospital of Zunyi Medical University Zunyi Guizhou China.

Institute of Neurological Disease and Department of Anesthesiology Translational Neuroscience Center, West China Hospital, Sichuan University Chengdu Sichuan China.

出版信息

Ibrain. 2021 Mar 28;7(1):21-28. doi: 10.1002/j.2769-2795.2021.tb00060.x. eCollection 2021 Mar.

Abstract

OBJECTIVE

Study the principle and possible mechanism of Ginkgo biloba in the treatment of Alzheimer's disease (AD) which is based on network pharmacology.

METHODS

The potential targets of active ingredients of Ginkgo biloba were collected by Traditional Chinese Medicine Integrated Database platform (TCMSP). TCMSP is a pharmacological system for drug discovery from Chinese herbal medicine. The disease targets of AD were searched and collected by the database of gene-disease associations (DisGeNET) and literature. The obtained targets were standardized by the UniProt database. STING network platform and Cytoscape were used to construct protein-protein interaction network (PPI) of the key targets. According to Materscape, we clarify the possible mechanism of action including Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) enrichment analysis.

RESULTS

The compound-target network contains 27 active ingredients, 191 related targets, 18 key targets, including PLAU, HMOX1, TNF, INSR, MPO, MAOB, IGF2, IL1B, ESR1, BCL2, ACHE, BAX, GSK3B, PPARG, SLC2A4, NOS3, CASP3, VEGFA. GO enrichment analysis has got a total of 640 GO items, including 609 biological process (BP) items (95.1%), 16 molecular function (MF) items (2.5%) and 15 cellular component (CC) items (2.4%). After KEGG enrichment, 44 pathways were obtained.

CONCLUSION

Through the construction of "component-target-pathway", GO biological function and KEGG pathway enrichment analysis were performed on core targets, and the possibility of Ginkgo biloba for the treatment of AD was explored from multiple targets and pathways, which provided a new approach for multi-target treatment.

摘要

目的

基于网络药理学研究银杏叶治疗阿尔茨海默病(AD)的作用原理及可能机制。

方法

通过中药整合数据库平台(TCMSP)收集银杏叶活性成分的潜在靶点。TCMSP是一个用于从中药中发现药物的药理系统。通过基因-疾病关联数据库(DisGeNET)和文献检索收集AD的疾病靶点。所得靶点通过UniProt数据库进行标准化。利用STRING网络平台和Cytoscape构建关键靶点的蛋白质-蛋白质相互作用网络(PPI)。根据Metascape,阐明包括京都基因与基因组百科全书(KEGG)通路和基因本体(GO)富集分析在内的可能作用机制。

结果

化合物-靶点网络包含27种活性成分、191个相关靶点、18个关键靶点,包括PLAU、HMOX1、TNF、INSR、MPO、MAOB、IGF2、IL1B、ESR1、BCL2、ACHE、BAX、GSK3B、PPARG、SLC2A4、NOS3、CASP3、VEGFA。GO富集分析共获得640个GO条目,包括609个生物学过程(BP)条目(95.1%)、16个分子功能(MF)条目(2.5%)和15个细胞成分(CC)条目(2.4%)。KEGG富集后获得44条通路。

结论

通过构建“成分-靶点-通路”,对核心靶点进行GO生物学功能和KEGG通路富集分析,从多个靶点和通路探索银杏叶治疗AD的可能性,为多靶点治疗提供了新途径。

相似文献

1
Analysis of the potential and mechanism of Ginkgo biloba in the treatment of Alzheimer's disease based on network pharmacology.
Ibrain. 2021 Mar 28;7(1):21-28. doi: 10.1002/j.2769-2795.2021.tb00060.x. eCollection 2021 Mar.
3
Network Pharmacology-Based Strategy to Investigate the Pharmacologic Mechanisms of Coptidis Rhizoma for the Treatment of Alzheimer's Disease.
Front Aging Neurosci. 2022 Jun 21;14:890046. doi: 10.3389/fnagi.2022.890046. eCollection 2022.
6
Study on Mechanism of Ginkgo biloba L. Leaves for the Treatment of Neurodegenerative Diseases Based on Network Pharmacology.
Neurochem Res. 2021 Jul;46(7):1881-1894. doi: 10.1007/s11064-021-03315-z. Epub 2021 May 14.
7
A network pharmacology approach to investigate the mechanism of Shuxuening injection in the treatment of ischemic stroke.
J Ethnopharmacol. 2020 Jul 15;257:112891. doi: 10.1016/j.jep.2020.112891. Epub 2020 Apr 18.
10
Network Pharmacology-Based Study of the Underlying Mechanisms of Huangqi Sijunzi Decoction for Alzheimer's Disease.
Evid Based Complement Alternat Med. 2021 Oct 5;2021:6480381. doi: 10.1155/2021/6480381. eCollection 2021.

引用本文的文献

1
Molecular Network Mechanism Analysis of Urine Stem Cells Against Retinal Aging.
Biochem Genet. 2024 Oct;62(5):4046-4066. doi: 10.1007/s10528-023-10487-6. Epub 2024 Jan 25.
2
Application value and challenge of traditional Chinese medicine carried by ZIF-8 in the therapy of ischemic stroke.
Ibrain. 2021 Dec 11;7(4):337-350. doi: 10.1002/ibra.12007. eCollection 2021 Winter.
3
The neuroprotective effects of Lutongkeli in traumatic brain injury rats by anti-apoptosis mechanism.
Acta Cir Bras. 2022 Sep 19;37(6):e370603. doi: 10.1590/acb370603. eCollection 2022.
4
Alzheimer-Compound Identification Based on Data Fusion and forgeNet_SVM.
Front Aging Neurosci. 2022 Jul 25;14:931729. doi: 10.3389/fnagi.2022.931729. eCollection 2022.
5
Single-cell RNA sequencing reveals B cell-related molecular biomarkers for Alzheimer's disease.
Exp Mol Med. 2021 Dec;53(12):1888-1901. doi: 10.1038/s12276-021-00714-8. Epub 2021 Dec 8.

本文引用的文献

1
JBPOS0101 regulates amyloid beta, tau, and glial cells in an Alzheimer's disease model.
PLoS One. 2020 Aug 13;15(8):e0237153. doi: 10.1371/journal.pone.0237153. eCollection 2020.
2
A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy.
Med Res Rev. 2021 Sep;41(5):2689-2745. doi: 10.1002/med.21719. Epub 2020 Aug 11.
3
Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer's Disease Therapy.
Molecules. 2020 Jul 23;25(15):3337. doi: 10.3390/molecules25153337.
5
GSK3β and Tau Protein in Alzheimer's Disease and Epilepsy.
Front Cell Neurosci. 2020 Mar 17;14:19. doi: 10.3389/fncel.2020.00019. eCollection 2020.
6
History and progress of hypotheses and clinical trials for Alzheimer's disease.
Signal Transduct Target Ther. 2019 Aug 23;4:29. doi: 10.1038/s41392-019-0063-8. eCollection 2019.
7
Risk factors for Alzheimer's disease.
Folia Neuropathol. 2019;57(2):87-105. doi: 10.5114/fn.2019.85929.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验